Lack of deal-making is restricting pharma innovation in Asia-Pacific; report

30 August 2019
2019_vials_lab_biotech_research_big

A new, first-of-its-kind report entitled “Pharmaceutical innovation in the APAC region: A quantitative company ranking and future outlook,” has been published by Clarivate Analytics plc.

The report provides insights on which countries/regions in Asia-Pacific (APAC) are most conducive to innovation, which companies lead the way today or are poised to lead tomorrow, and how a company’s innovation profile affects its success. Report findings show, while exhibiting strong drug development capability, greater early-stage partnering and increased academic collaboration are needed for companies in the APAC region to expand their global footprint.

Key findings:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical